Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 8/20 | 0.40 |
| ▸ | PPARA | Q07869 | 8/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.38 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGAV | P06756 | 2/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.38 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174814 | 1.00 | PTGS2 (0.42) | PTGS2PPARGPPARAPPARDSRR | |
| SCHEMBL2173074 | 0.99 | PTGS2 (0.44) | PTGS2PPARGPPARAPPARDSRR | |
| SCHEMBL2173079 | 0.99 | PTGS2 (0.44) | PTGS2PPARGPPARAPPARDSRR | |
| SCHEMBL3946797 | 0.95 | PTGS2 (0.44) | PTGS2PPARGPPARAPPARDMMEL1 | |
| SCHEMBL2172731 | 0.94 | PPARA (0.46) | PTGS2PPARGPPARAPPARDLTB4R2 | |
| SCHEMBL2172727 | 0.94 | PPARA (0.46) | PTGS2PPARGPPARAPPARDLTB4R2 | |
| SCHEMBL2172772 | 0.94 | PPARA (0.46) | PTGS2PPARGPPARAPPARDLTB4R2 | |
| SCHEMBL2173206 | 0.93 | PPARA (0.45) | PTGS2PPARGPPARAPPARDITGB3 | |
| SCHEMBL2174476 | 0.93 | PPARA (0.45) | PTGS2PPARGPPARAPPARDITGB3 | |
| SCHEMBL2173202 | 0.93 | PPARA (0.45) | PTGS2PPARGPPARAPPARDITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973063-B2 | Methods for activating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-07-05 | — | — | US | claimed |
| EP-1742608-B1 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR(GAMMA) TYPE RECEPTORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-02-24 | — | — | EP | claimed |
| US-20100035988-A1 | Methods for activating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-02-11 | — | — | US | claimed |
| US-7626054-B2 | Biaromatic compounds which activate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | claimed |
| US-20070112070-A1 | Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-17 | — | — | US | claimed |
| US-7973063-B2 | Methods for activating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-07-05 | — | — | US | disclosed |
| EP-1742608-B1 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR(GAMMA) TYPE RECEPTORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-02-24 | — | — | EP | disclosed |
| US-20100035988-A1 | Methods for activating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-02-11 | — | — | US | disclosed |
| US-7626054-B2 | Biaromatic compounds which activate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | disclosed |
| US-20070112070-A1 | Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112070-A1 | Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | PTGS2 925/4885PPARG 1/4885PPARA 3/4885 |
| US-20100035988-A1 | Methods for activating PPAR gamma-type receptors | PPARG, PPARA, PPARD | PTGS2 452/4885PPARG 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.